Choroid plexus epithelial cells are enriched in mRNA for proteins such as the iron carrier transferrin, which acts as a trophic factor in the brain. Choroid plexus epithelial ceils also have a high density of 5-HT,, receptors linked to activation of the phosphoinositide (PI) hydrolysis second messenger system. The present studies show that the 5-HT,,/ 5-HT, receptor agonist 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) potently increases PI hydrolysis and the levels of transferrin in primary cultures of rat choroid plexus epithelial cells. These effects are blocked by the 5-HT,,/ 5-HT, receptor antagonists mesulergine and mianserin, but not by the 5-HT, receptor-selective antagonist spiperone. Similarly, mesulergine and mianserin, but not spiperone, block the increases in transferrin levels and PI hydrolysis elicited by 5carboxamidotryptamine (5CT), a 5-HT, receptor-selective agonist, and by serotonin.
We conclude, therefore, that 5-HT,, receptor activation in the choroid plexus leads to an increase in the production of transferrin. By promoting transferrin synthesis in the choroid plexus, 5-HT may indirectly influence brain development and differentiation.
Choroid plexus contains a monolayer of cuboidal epithelial cells with three main functions: to serve as the blood-cerebrospinal fluid (CSF) barrier, to regulate CSF production, and to modulate CSF composition (Cserr, 1975) . The choroid plexus is enriched in a variety of mRNA species encoding transport proteins such as transferrin (Dickson et al., 1985; Aldred et al., 1987b) , transthyretin (Dickson et al., 1985; Stauder et al., 1986) and ceruloplasmin (Aldred et al., 1987a) . Since these proteins are enriched in the CSF relative to the plasma, it is thought that the choroid plexus synthesizes and releases them into the CSF. Consistent with this, we have recently shown that choroid plexus cells in primary culture synthesize transferrin and release it into the medium (Tsutsumi et al., 1989) . Transferrin is an important source of iron (Laskey et al., 1988) , and has also been shown to have growth factor-like actions independent of its ability to supply iron (Toran-Allerand, 1980; Beach et al., 1983; Ekblom et al., 1983; Espinosa de 10s Monteros et al., 1989) . Transferrin mRNA levels are high in choroid plexus and moderately so in oligodendrocytes, but are negligible in other brain structures (Toran-Allerand, 1980; Bloch et al., 1985) . The choroid plexus may thus be an important source of transferrin for brain cells.
Choroid plexus receives serotonergic innervation from the raphe, and the basolateral surface of the epithelial cells may also be exposed to 5-HT in the blood (Moskowitz et al., 1979; Napoleone et al., 1982) . The epithelial cells have a high density of 5-HT,, receptors that are apparently localized to the apical surface (Giordano and Hartig, 1987) . Thus, 5-HT in the CSF could play an important role in the choroid plexus. 5-HT is released into the CSF via a group of neurons, termed supraependymal fibers, that release their contents directly into the CSF (Aghajanian and Gallager, 1975; Tramu et al., 1983; Matsuura et al., 1985) . The concentration of 5-HT in the CSF has been reported to be in the 1 O-100 nM range (Le Quan-Bui et al., 1982; Volicer et al., 1985; Linnoila et al., 1986) , which would be sufficient to activate the 5-HT,, receptor. 5-HT,, receptors in choroid plexus are capable of activating the phosphoinositide (PI) hydrolysis signal transduction pathway . Furthermore, these receptors become supersensitive when 5-HT neurons are destroyed (Conn et al., 1987) . These findings, suggesting that 5-HT,, receptors in choroid plexus are innervated and functionally active, have spurred interest in a possible physiological role for these receptors. Our studies of the regulation of transfer& synthesis showed that 5-HT applied to primary cultures of choroid plexus cells increases transferrin production and increases the steady-state level of transfenin mRNA (Tsutsumi et al., 1989) . Thus, 5-HT may indirectly influence brain development by increasing the production of a trophic factor by the choroid plexus. The present studies were designed to identify the receptor that mediates this effect.
Materials and Methods
Materials andanimals. Twenty-day-old male Sprague-Dawley rats were purchased from Sasco. Inc. (Omaha. NE). Cell media. dialvzed calf serum, fetal bovine serum, gentamicin, L-glutamine, trypsin, and vitamin and amino acid supplements were obtained from GIBCO/Bethesda Research Laboratories Life Technologies, Inc. (Grand Island, NY). 3H-myo-inositol, 3H-thymidine, '*P-aCTP, and NaY were obtained from New England Nuclear Corp. (Boston, MA). l-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane (DOI), S-carboxamidotryptamine (5-CT), mianserin, and spiperone were purchased from Research Biochemicals, Inc. (Wayland, MA), and mesulergine, from Sandoz Pharmaceuticals (East Hanover, NJ). Transferrin and rabbit anti-rat transferrin primary antibody were purchased from Organon Teknika Corp. (West Chester, PA), and pronase, from Boehringer Mannheim Biochemicals (Indianapolis, IN). The Riboprobe Gemini System was purchased from Promega Corporation (Madison, WI), and Nytran membranes, from Schleicher and Schuell (Keene, NH). Other chemicals were purchased from Sigma Chemical Co. (St. Louis, MO).
Epithelial cell preparation. The preparation is a modification of the method of Crook et al. (198 1 Choroid plexi were treated with pronase exactly as described above. After the pooled cells were spun down, the supematant was harvested and spun for 10 min at 900 x g, and the pellet was resuspended and distributed into 35-mm plates containing Dulbecco's modified Eagle's medium (DMEM) with 20% fetal bovine serum, L-glutamine (2 mM), gentamicin (lOpg/ml), and vitamin and amino acid supplements. The cells had the characteristic morphology of fibroblasts, divided rapidly in culture, and stained intensely when incubated with antibodies to fibronectin. The first plating contained some epithelial contamination, which disappeared upon splitting. For studies of transferrin mRNA and nrotein. cells were transferred to F12 without supplements 48 hr before initiation of treatment. For phosphoinositide hydrolysis studies, medium was replaced with DMEM containing 2% dialyzed calf serum 24 hr before the addition of 'H-myoinositol.
Drug treatment.
Beginning on the fourth day of culture, cells were treated for 4 d with either drug or vehicle, with a change of medium on the seventh day. On the last day of treatment, 3H-myo-inositol was added. The following day, phosphoinositide hydrolysis was measured by incubating with 10 mM lithium chloride for 45 min. Medium was collected for analysis of transferrin content, and cells were harvested for measurement of )H-inositol monophosphate (3H-IP) formation. Radioimmunoassay. Transferrin in the medium was measured by radioimmunoassayas described previously (Tsutsumi et al., 1989) . Briefly, medium was incubated with rabbit anti-rat transferrin primary antibody and '251-transferrin for 60 min, followed by an additional incubation with a secondary goat anti-rabbit antibody. The complex was precipitated at 4°C with 13% polyethylene glycol and spun at 2000 x g, and the pellet was analyzed for radioactivity using a Beckmann gamma counter. Samples were normalized for DNA content using a fluorescence method (Karsten and Wollenberger, 1977) . Control experiments showed that lithium chloride, which was added for the phosphoinositide hydrolysis assay, did not interfere with the transferrin radioimmunoassay.
Phosphoinositide hydrolysis.
The procedure was based on that of Berridge (1982) as modified by Tsutsumi and Sanders-Bush (1990) . For acute studies, cells were incubated overnight with 1 &/ml )H-myoinositol in CMRL 1066 medium, which has only 0.2% of the inositol contained in F12. Labeled cells were incubated with 10 mM lithium chloride and 10 PM pargyline for 15 min, and then with agonist or vehicle for 30 min. The reaction was stopped by removal of medium and addition of 50 ~1 of methanol. Cells were disrupted by sonication in a buffer containing 0.15% trypsin. The inositol phosphates were extracted with chloroform/methanol, and 3H-IP was separated by anion exchange chromatography. 'H-IP was collected and counted in a Packard 1900CA liquid scintillation counter. For chronic studies, cells were labeled on the fourth day of drug treatment (see above) with 3H-myoinositol (5 &i/ml) overnight, and were then incubated with 10 mM lithium chloride for 45 min. No additional agonist or antagonist was added in these studies. All further procedures were the same as already described.
'H-thymidine assay. Choroid plexus epithelial cells were removed from serum and kept in Ham's F12 for 2 d. Cells were then incubated 24 hr with 2 &i/ml 'H-thymidine in F12 containing vehicle or drug. Plates were rinsed with phosphate-buffered saline, and cells were fixed with two 10 min methanol washes. The cells were washed by submerging eight times in tap water, dried, and solubilized for 2 hr at 60" in 0.2N NaOH/ 1 O/o SDS. The samples were counted in a Packard 1900CA liquid scintillation counter using Aquasol scintillation fluid (Du Pont New England Nuclear, Boston, MA).
Northern analysis. Cells plated in 35-mm wells were maintained and treated with drugs as described previously. After 4 d of treatment, RNA was isolated using a modification of the method of MacDonald (1987) . Medium was removed, and buffer (4 M guanidinium isothiocyanate, 25 mM sodium citrate, 0.5% sarkosyl, 0.1 M P-mercaptoethanol) was added. The cell lysate was sheared five times through a 22-gauge needle, layered on a cushion of 5.7 M cesium chloride, and centrifuged at 140,000 x g for 23 hr at 20°C. The resulting pellet was resuspended, precipitated with ethanol, and quantified by measuring absorbance at 260 nm. Aliquots representing 5 fig of total RNA were separated in a 1.2% agarose, 18% formaldehyde, 20 mM 3-[N-morpholinol-propane sulfonic acid gel for 4 hr at 25 V. The gel was capillary blotted overnight to a Nytran membrane, and the RNA was immobilized by baking 1 hr at 80°C. Hybridization. cRNA probes were prepared by in vitro transcription using the Promega Gemini II system. The transferrin cRNA probe was synthesized from a plasmid (provided by Dr. Michael Skinner, Vanderbilt University) containing a 390 base pair (bp) fragment of rat transferrin cDNA (Huggenvik et al., 1987) . The cyclophilin probe was made from a plasmid with a 680 bp insert (Danielson et al., 1988 ) (provided by Dr. Robert Coffey, Vanderbilt). Probes were labeled to a specific activity of lo8 cpm/pg using 32P-olCTP and were purified on a 9 M urea, 4% aearose. 90 mM Tris/90 mM boric acid/l0 mM EDTA eel. Blots were irehybridized at 42°C for 6 hr in 10 ml of buffer [50% formamide, 10% dextran sulfate, 5x SSPE (750 mM NaCl, 500 mM NaH,PO,, 5 mM EDTA), 1% SDS], after which 10' cpm of probe was added along with 1 mg of sheared salmon sperm DNA. Hybridization was allowed to proceed for 16 hr. Blots were washed three times at 65°C in 2 x saline-sodium citrate (SSC), 0.1% SDS for 30 min, followed by three more 30 min washes at 65°C in 0.2x SSC. 0.1% SDS. The blots were then exposed at -70°C to Kodak X-OMAT film, and bands were quantified using an LKB laser densitometer.
Results
Effects of 5-HT receptor agonists. 5-HT, 5-CT, and DO1 increased PI hydrolysis in cultured choroid plexus epithelial cells (Fig. 1) . 5-HT and 5-CT were full agonists, producing an average ninefold increase over basal. 5-CT was less potent than was 5-HT. DOI, on the other hand, was essentially equipotent with 5-HT, but produced a submaximal response (60%), apparently acting as a partial agonist in this system. The order of potency (5-HT = DO1 >> 5-CT) is consistent with activation of the 5-HT,, receptor.
In additional experiments, cells were treated with DOI, 5-CT, or 5-HT for 4 d and PI hydrolysis and transferrin production were measured. Cells were treated with drug(s) as usual on day 4, and 3H-myo-inositol was added as well. The next day, lithium chloride was added to start the accumulation of IP; no additional drugs were added. After 45 min, the medium was removed for analysis of transferrin content, and the cells were harvested for measurement of 3H-IP formation. DO1 (Fig. 2) and 5-CT (Fig.  3) dose-dependently increased transferrin production and PI hydrolysis. Consistent with the acute studies, DO1 was more potent than was 5-CT. The indicated concentration of drug was added daily, so the actual concentration at the time of the PI hydrolysis assay was probably larger than indicated. This presumably explains the apparent differences in potencies in the chronic versus the single-dose experiments.
Although a comparison of Figures 2 and 3 suggests that DO1 and 5-CT elicit different maximum transfetin responses, additional studies in which the two drugs were analyzed concurrently revealed no significant difference. This is unexpected in light of the evidence that DO1 is a partial agonist for eliciting PI hydrolysis.
In some experiments, cells were harvested and assayed for transferrin content. The intracellular levels of transfertin were below the limit of detection (z 10 ng) even in the presence of DOI. When two wells of cells were combined, the amount of transferrin was still < 10 ng, while aliquots representing onethird of the medium from one well contained between 30 and dine into DNA. Although serum alone increased 3H-thymidine incorporation, there was no additive effect when DO1 was present (Table 1) .
Antagonism of the effects of 5-HT agonists. The 5-HT,,/5-HT, receptor antagonists mesulergine and miansetin blocked both transfetin production and PI hydrolysis in response to DO1 (Fig. 4) and 5-CT (Fig. 5) , while spiperone, a 5-HT, receptorselective antagonist, had no effect. Similarly, mesulergine and mianserin, but not spiperone, blocked the effect of 5-HT on transferrin levels (Fig. 6) . The antagonists had no effect on basal transferrin levels. To examine the possibility that spiperone's inability to block reflects inactivation of the drug, aliquots of the conditioned medium were removed and the ability to block 5-HT-stimulated PI hydrolysis was determined in NIH3T3 cells transfected with 5-HT, receptor mRNA (Julius et al., 1990) . Spiperone from the medium reduced the 5-fold PI hydrolysis response of 200 nM 5-HT to 1.5-fold of basal, indicating that the drug was indeed still active. The possibility that mesulergine actually did not block transferrin production but instead blocked secretion of the protein into the cell culture medium was tested by analyzing the cellular levels of transferrin. Transferrin in cells was below the limit of detection regardless of drug treatment (data not shown). If mesulergine were blocking transfertin release, cell levels of transferrin should have increased to readily detectable values.
The studies described so far utilized only single concentrations of antagonist. In additional experiments, increasing concentrations of mesulergine were tested with a near-maximal (33 nM) concentration of DOI. Mesulergine potently and dose dependently (IC,, = 3 nM) blocked the ability of DO1 to increase PI hydrolysis and to increase transfetin levels, with complete inhibition at 100 nM (Fig. 7) .
Time course studies. Transferrin measurements were routinely performed after 4 d of drug treatment, because preliminary studies suggested that increases in transferrin levels were delayed in onset. Additional experiments were designed to determine whether continuous agonist activation was needed in order to have an effect, or if an initial stimulation with DO1 was sufficient to produce a delayed increase in transfertin. Because DO1 could not be washed out of the cells (data not shown), 1 PM mesulergine was added at various times after the addition of DO1 to block the effect of the agonist during the subsequent incubation. As demonstrated in Figure 8 , 3 d of exposure to DO1 was needed to give a maximum effect, although a significant increase was seen after 2 d. These studies demonstrate that an initial brief stimulation of the cells with DO1 was not sufficient to increase transferrin production. Instead, the continued presence of the drug is necessary, perhaps indicating that global, long-term changes in cell function (e.g., differentiation) must occur before transferrin production is seen.
Characteristics OfJibroblasts from rat choroidplexux The major contaminating cells in the primary cultures of epithelial cells had morphological features of fibroblasts. To determine whether the fibroblasts contributed to either the transferrin or the PI hydrolysis response, the cell isolation procedure was modified to establish cultures of fibroblasts. Unlike epithelial cells, the fibroblasts had negligible levels of transferrin mRNA (Fig. 9) , and transferrin levels in the cell culture medium were undetectable, even after 4 d of treatment with DOI. 5-HT increased PI hydrolysis in these cells, with an EC,, of 250 nM. In contrast to the effect in the epithelial cells, 5-HT-induced PI hydrolysis in fibroblasts was blocked by spiperone (Fig. 10) .
Discussion
Choroid plexus contains a high density of 5-HT,, receptors (Yagaloff and Hartig, 1985) that are linked to the PI hydrolysis signaling cascade 1986). 5-HT applied to primary cultures of choroid plexus cells increases the level of transferrin, an iron carrier protein that also has growth factor-like effects (Tsutsumi et al., 1989) . (Julius et al., 1989) . The present studies show that, rather than acting as a mitogenic stimulus, 5-HT,, receptor activation in choroid plexus has effects analogous to the recently described action of 5-HT in astrocyte cultures. In these cells, 5-HT increases the levels of another trophic substance, S 1 OO& apparently by interacting with 5-HT,, receptors (Whitaker Azmitia and Azmitia, 1989; Azmitia et al., 1990) . The present studies utilized a primary cell culture system as a model of choroid plexus epithelial cells, but it is possible that a contaminating cell type may have contributed to the observed effects. Culture conditions were optimized to minimize contamination of the epithelial cultures with fibroblasts; however, it is still possible that 5-HT may have interacted with remaining fibroblasts or an unknown cell type to increase transferrin. To test this possibility directly, cultures of fibroblasts were established; after passage, no epithelial cells were evident in these cultures. Transferrin mRNA levels were undetectable in the fibroblast cultures, and in addition, transferrin protein was not present in controls or in cultures treated with DOI. Therefore, the fibroblasts do not appear to contribute directly to the increased transfenin level found after treatment with 5-HT receptor agonists.
Previous studies were unsuccessful in demonstrating blockade of the 5-HT-induced transferrin increase by 5-HT,, receptor antagonists (Tsutsumi and Sanders-Bush, 1990 ). However, the present studies show a reproducible and complete blockade of DOI, 5-CT, and 5-HT. The explanation for this discrepancy is not entirely clear. In the original studies, a high concentration of 5-HT was used, which may have other effects on the cultured I cells that mask the 5-HT,, receptor-mediated effect. One interesting possibility is that 5-HT acts on another 5-HT receptor; however, no other 5-HT receptors were detected in binding studies ofintact choroid plexus Yagaloff and Hartig, 1985) . In fibroblast cultures isolated from choroid plexus, a 5-HT, receptor-mediated PI hydrolysis response has been characterized (Barker et al., 199 1; present results) , although the density of sites is too low for radioligand binding analyses. High concentrations of 5-HT would activate this receptor; however, the antagonists used should also block 5-HT, receptor-mediated effects. At high concentrations, 5-HT may have non-receptor-mediated effects. This was the case with 5-HT antagonists; Tsutsumi and Sanders-Bush (1990) found that high concentrations of mianserin and other 5-HT antagonists increased basal transferrin levels. In the present studies, where lower concentrations of antagonists were used, no change in transfen-in levels was detected. Given the possibility of nonreceptor effects, the present demonstration that the effects of 5-HT agonists can be blocked by selective antagonists is especially important.
The DOI-induced increase in transfer&r is delayed, suggesting that the synthesis of transfenin may reflect or be secondary to other changes in the cell. We have evidence that DO1 treatment increases levels of c-j& mRNA in the cells (T. M. Esterle and E. Sanders-Bush, unpublished observations). Since Fos protein is known to increase the transcription of genes that have an AP-1 regulatory region (Morgan and Curran, 1988) , it is possible that the transcription of specific target genes may be influenced by treatment with a 5-HT,, receptor agonist. Whether transfen-in is one of the target genes whose transcription is influenced remains to be seen. The 5' upstream region of the transferrin gene has two regions with some homology to the AP-1 site, and Tsutsumi et al. (1989) showed that 5-HT increases transferrin mRNA in choroid plexus cultures. Even if the transferrin gene is not a direct target, Fos may increase the transcription of other genes that contribute to increased synthesis of transferrin. The finding that more than 2 d is required to elicit a full transferrin response suggests that multiple intervening events are invoked between receptor activation and protein production.
In conclusion, the present studies demonstrate that activation of the 5-HT,, receptor in primary cultures of choroid plexus epithelial cells results in an increased level of transfer@ an iron-carrying protein that also has growth factor-like effects.
Thus, 5-HT may indirectly serve as a growth or trophic factor in the choroid plexus. 5-HT has been shown to have growth factor-like effects in a number of other systems. In embryonic rat brain, it influences the development of its target neurons (Lauder, 1983; Lauder et al., 1988) . 5-HT also increases 3H-thymidine incorporation in fibroblasts via activation of the 5-HT,, receptor (Seuwen et al., 1988) and in aortic smooth muscle cells following pertussis toxin-sensitive activation of PI hydrolysis (Nemecek et al., 1986) . Further, in fibroblasts transfected with 5-HT,, or 5-HT, receptor cDNA, 5-HT acts as a protooncogene, presumably by activating PI hydrolysis in these cells (Julius et al., 1990) . By contrast, 5-HT,, receptor activation had no effect on 3H-thymidine incorporation in our primary cultures of choroid plexus epithelial cells that are presumably differentiated in culture. Our studies suggest that 5-HT's growth factor-like activity is manifested as an ability to maintain the differentiated phenotype in primary cultures of choroid plexus epithelial cells. The demonstration that the SHT,, receptor mRNA in choroid plexus is expressed early in fetal development (Roth et al., 1991) combined with the present evidence that activation of the 5-HT,, receptor has trophic effects, suggests the possibility that 5-HT acts as a developmental signal in the choroid plexus. Future studies should address this possibility by exploring the role of the 5-HT,, receptor in developing animals.
